Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease (MRD) in Myeloma: Independent Outcome Prediction and Sequential Survival Benefits per Log Tumour Reduction

Andy C Rawstron, BSc, PhD, Walter Gregory, PhD, Ruth M de Tute, Faith E Davies, MD, Susan E Bell, DPhil, Mark T Drayson, MDPhD, Gordon Cook, MD, Graham H Jackson, MD, James A Child, Gareth J. Morgan, MD PhD, Roger G Owen

Blood (2014) 124 (21): 3416.

https://doi.org/10.1182/blood.V124.21.3416.3416

Published: 2014

Journal Articles

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

Fiona M. Ross, DPhil, Laura Chiecchio, PhD, GianPaolo Dagrada, BSc, William J Tapper, PhD, Zoe J Konn, BSc, Kan Luk Cheung, BSc, Rebecca KM Protheroe, BSc, David M Stockley, BSc, Susan E Bell, DPhil, Walter M Gregory, PhD, Alexander J Szubert, MSc, Gordon Cook, MD, Roger G. Owen, MD, Mark T. Drayson, MD, Graham Jackson, DM, Faith Davies, MD, PhD, J. Anthony Child, MD, Gareth J Morgan, MD, PhD

Blood (2010) 116 (21): 2980.

https://doi.org/10.1182/blood.V116.21.2980.2980

Published: 2010

Journal Articles

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Gareth J Morgan, MD, PhD, Faith E Davies, MD, Walter M Gregory, Susan E Bell, Alex J Szubert, Kim Cocks, Nuria Navarro Coy, Mark T Drayson, Roger G Owen, Fiona M Ross, DPhil, Graham H Jackson, J. Anthony Child

Blood (2009) 114 (22): 352.

https://doi.org/10.1182/blood.V114.22.352.352

Published: 2009

Journal Articles

Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation

Gareth J Morgan, MD, PhD, Graham H Jackson, Faith E Davies, MD, Mark T Drayson, Roger G Owen, Walter M Gregory, Dena C Cohen, Alex J. Szubert, Susan E Bell, Fiona Ross, James A Child

Blood (2008) 112 (11): 656.

https://doi.org/10.1182/blood.V112.11.656.656

Published: 2008

Journal Articles

Follow up Analysis for MRC Myeloma VII Trial.

Gareth J. Morgan, PhD, Faith E. Davies, MD, Kim Hawkins, MSc, Susan E. Bell, DPhil, Julia M. Brown, MSc, Roger G. Owen, MD, Mark T. Drayson, PhD, Peter J. Selby, MD, Anthony J. Child, MD, for the Medical Research Council Adult Leukaemia Working Party

Blood (2004) 104 (11): 927.

https://doi.org/10.1182/blood.V104.11.927.927

Published: 2004

NARROW

Minimal Residual Disease (MRD) in Myeloma: Independent Outcome Prediction and Sequential Survival Benefits per Log Tumour Reduction

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation

Follow up Analysis for MRC Myeloma VII Trial.

Email alerts

ASH Publications

American Society of Hematology

Minimal Residual Disease (MRD) in Myeloma: Independent Outcome Prediction and Sequential Survival Benefits per Log Tumour Reduction

Deletion 13, Detected by Metaphase Analysis, Is Not a Significant Prognostic Indicator In Myeloma

The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation

Follow up Analysis for MRC Myeloma VII Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only